“…The vaccines rolled out nationally included: Sinopharm, Sinovac and CanSinoBIO (China), AstraZeneca (UK), Moderna and Pfizer (USA), Sputnik (Russia), and PakVac (China/Pakistan). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…This study was designed to estimate the prevalence of adverse events after the first dose of the Covishield (AstraZeneca) vaccine among physicians in Bangladesh. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The four different COVID-19 vaccines authorized in Spain during the time-period studied were: BNT162b2 (Pfizer); ChAdOx1 nCoV-19 (AstraZeneca), mRNA-1273 (Moderna); Ad26.COV2.S (Janssen). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…RESULTS: Thirty-three (71.7%), nine (19.6%), and three (6.5%) patients were administered AZD1222 (AstraZeneca), BNT162b2 (Pfizer/BioNTech), and JNJ-78436735 (Johnson and Johnson) vaccines, respectively. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Results indicated that the majority of respondents administered Pfizer BioNtech vaccine (81%, n = 809); followed by AstraZeneca (16%, n = 155); and Moderna (3%, n = 34). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In contrast, the second dose of Moderna vaccine (aOR: 0.794; 95% CI: 0.683–0.922), AstraZeneca vaccine (aOR: 0.691; 95% CI: 0.509–0.939), strong symptoms from side effects after the second dose of the COVID-19 vaccine (aOR: 0.615; 95% CI: 0.404–0.935) were independent factors most associated with a lower uptake of the COVID-19 vaccine booster dose. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…One hundred and thirteen fully vaccinated individuals were included at 6 ± 1 weeks after second vaccination (BioNTech/Pfizer (69.9%), AstraZeneca (21.2%), and Moderna (8.9%)). In a cross-sectional and single-centre study design, we compared titres of neutralising antibodies between patients with (n = 51) and without (n = 62) medication with JAK inhibitors. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…When compared to the Sinopharm vaccines, the OxfordAstraZeneca, Pfizer-BioNTech, and Moderna vaccines were 4.51 times (95% CI: 2.53–8.04), 5.37 times (95% CI: 2.57–11.22), and 4.28 times (95% CI: 2.28–8.05) likelier to produce side effects. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…No serious adverse events or fatalities were seen, and most studies reported milder and lesser adverse events with Covaxin when compared with other vaccines, especially Oxford-Astra Zeneca’s AZD1222 (Covishield). The immunogenicity performance of Covaxin, which provided significant protection only after the second dose, was mediocre and it was consistently surpassed by Covishield. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The study was conducted between July 2021 and 2022 in a sample of adult patients presenting to hospitals across Jordan and receiving one of the three vaccines – Pfizer (BNT162b2), Astra Zeneca (ChAdOx1-S), or Sinopharm (BBIBP-CorV). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…FUNDING: The study was sponsored by AstraZeneca.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The mean age of patients was 58.7 ± 16.6 years and 55 cases (62.5%) were male. AstraZeneca was the most-reported vaccine associated with GBS with 52 cases (59.1%) followed by Pfizer with 20 cases (22.7%). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Most of the published cases occurred in temporal association with the Pfizer vaccine (BNT162b2), followed by the AstraZeneca vaccine (ChAdOX1 nCoV-19). CONCLUSIONS: It is not possible to establish a causal relationship between these adverse events and COVID-19 vaccines with the currently existing data, nor to calculate the frequency of appearance of these disorders. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…However, limited information is available in lactating women receiving other vaccine platforms used in developing countries, such as the inactivated SARS-CoV-2 vaccine BBIBP-CorV (Sinopharm) and the non-replicating adenovirus vaccines Sputnik V (Gamaleya Institute) and ChAdOx1-S (Oxford AstraZeneca). METHODS: Here, we evaluated anti-SARS-CoV-2 IgG and IgA levels in both serum and milk samples using a longitudinal and a cross-sectional cohort of 208 breastfeeding vaccinated women from Argentina with or without previous SARS-CoV-2 infection. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…COVID-19 symptoms are similar to those of viral flu but may be more severe, these symptoms can be defended by vaccines, the most distributed 6 candidate vaccines are Pfizer, BioNTech, Moderna, Johnson & Johnson/Janssen AstraZeneca, Sinopharm, Sinovac. In Sudan, the virus has rapidly spread in the country, causing a total of 37,138 confirmed cases with 2,776 deaths till July 21, 2021. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Most of the published cases occurred in temporal association with the Pfizer vaccine (BNT162b2), followed by the AstraZeneca vaccine (ChAdOX1-S). CONCLUSIONS: It is not possible to establish a causal relationship between these adverse events and COVID-19 vaccines with the currently existing data, nor to calculate the frequency of appearance of these disorders. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Negative vaccine information related to the Oxford/AstraZeneca vaccine was the most common, particularly in March and April 2021. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…CASE PRESENTATION: Two otherwise healthy patients, a 49-year-old man and a 39-year-old woman, developed unilateral hypoglossal nerve palsy 10 and 7 days after the second SARS-CoV-2-vaccination (AstraZeneca and BioNTech/Pfizer), respectively. In both subjects, needle electromyography showed denervation and rarefication of motor units. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…INTERPRETATION: Dapagliflozin improves liver metabolism via hepatic autophagy, and plasma valine and leucine levels may reflect its metabolic effect. FUNDING: AstraZeneca K.K., 10.13039/501100013170Ono Pharmaceutical Co., Ltd., 10.13039/501100001700Ministry of Education, Culture, Sports, Science and Technology (10.13039/501100001700MEXT), 10.13039/501100001691Japan Society for the Promotion of Science (10.13039/501100001691JSPS), 10.13039/100009619Japan Agency for Medical Research and Development (10.13039/100009619AMED), 10.13039/100015758Novo Nordisk Pharma Ltd., and 10.13039/100008695Japan Foundation for Applied Enzymology, and MSD Life Science Foundation International.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso